The global metabolic acidosis market size is estimated to be valued at USD 188.7 Million in 2025. It can reach a valuation of USD 285.6 Million by 2032, by exhibiting a CAGR of 6.1% throughout the forecast period (2025-2032).  

The market growth is driven by the prevalence of metabolic acidosis in the elderly and the rising occurrence of chronic kidney disease (CKD). Efforts for improving the efficacy of alkali treatments and the popularity of hydrochloric acid binders for the treatment of metabolic acidosis can facilitate the market growth.

However, the lack of FDA-approved therapies for the treatment of metabolic acidosis can limit its market growth.

Key Market Insights

The metabolic acidosis market growth is driven by the development of home-based devices for monitoring acid-base levels and personalized medicine based on kidney profiles.

• By type, the chronic metabolic acidosis segment is expected to capture a 44.2% share of the market in 2025. This can be attributed to the high prevalence of CKD and persistent acidosis, which accelerates CKD.
• By treatment, the dialysis segment is expected to capture a 36% share of the market in 2025. This can be attributed to the demand for medical procedure in patients with end-stage renal disease (ESRD).
• By end user, the specialty clinics segment is expected to grow the fastest during the forecast period. This can be on account of nephrology centers that offer metabolic acidosis care. The preference for outpatient care and the mushrooming of specialty clinics can enable the segment’s growth over the forecast period.
• By region, Europe is anticipated to perform exceptionally during the forecast period. This can be attributed to investments in nephrology networks, the adoption of home monitoring tools, and initiatives for the screening of metabolic acidosis protocols for CKD.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/metabolic-acidosis-market

Metabolic Acidosis Market Report Coverage

Market Dynamics

The increasing cases of metabolic acidosis in children is expected to drive the market growth significantly. The complications from unresolved metabolic acidosis can lead to renal tubular acidosis. The urgent need for the detection of hypoglycemia in neonates can drive the market growth. The data from tests on animal and tissue studies can have a significant effect on the drugs used to maintain calcium levels in patients to prevent nephrolithiasis.

The use of sodium citrate as an alternative to sodium bicarbonate due to its tolerance level among patients can bolster the market growth over the forecast period. The demand for active supplements that assist in CKD disease recovery and continuous renal replacement therapy can pave the way for clinical trials.

Market Opportunity: Emerging Sodium-free Therapeutic Options

The development of sodium-free therapeutic options in the form of polymers that act as binding agents can open new market growth opportunities. The exacerbation of hypertension and congestive heart failure in CKD patients has created the demand for sodium-free treatments that correct acid-base levels. Favorable reimbursement packages for agents with cardiovascular safety in focus can gain attention as the next standard of care in chronic metabolic acidosis management.

Market Challenge: Technical and Regulatory Barriers

The technical and regulatory barriers, such as the requirement of specialized personnel and equipment, can limit the market growth. Regions with inadequate healthcare infrastructure will be hit the hardest by this challenge. Rigorous requirements for clinical trials can extend the time-to-market duration of medicines, which can deprive patients with CKD when they need it the most.

Analyst’s View

• The increasing cases of kidney disorders is expected to drive the metabolic acidosis market growth.
• The dialysis segment is anticipated to capture a significant market share in 2025 owing to the effective treatment of hemodialysis in ESRD patients.
• Key players are investing in the development of drugs for the correction of metabolic acidosis. 

Recent Developments

Milla Pharmaceuticals received the approval of the U.S. FDA on January 30, 2025, for the production of A.forall. It is a generic version of Hospira's THAM Solution Tromethamine Injection. 

Competitor Insights

• Zydus Cadila
• Advicenne Pharma
• Amneal Pharmaceuticals
• Novartis
• Relypsa, Inc.
• Zagociguat
• Tisento Therapeutics
• Fresenius Medical Care
• Tricida

Market Segmentation

• By Type

• Acute Metabolic Acidosis
• Drug-induced Acidosis
• Lactic Acidosis
• Chronic Metabolic Acidosis
• Renal Tubular Acidosis
• Diabetic Ketoacidosis

• By Treatment

• Bicarbonate Therapy
• Oral Bicarbonate
• Intravenous Bicarbonate
• Dialysis
• Hemodialysis
• Peritoneal Dialysis
• Pharmacological Agents
• Sodium Bicarbonate Tablets
• Potassium Citrate Supplements

• By End User

• Hospitals
• Inpatient Services
• Outpatient Services
• Clinics
• Specialty Clinics
• General Clinics
• Homecare Settings
• Home Dialysis
• Home Medication Management

Regional Insights

• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Italy
  • Germany
  • U.K.
  • Spain
  • Russia
  • France
  • Rest of Europe
• Asia Pacific
  • South Korea
  • India
  • China
  • Japan
  • Australia
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa